Evolving treatment modalities for immune thrombocytopenia in adults
The management of patients with relapsed or refractory immune thrombocytopenia (ITP) remains challenging for hematologists. While there are a multitude of drugs available, it is largely an individualized management based on patient preferences, side effects, previous treatment received, and response...
Main Authors: | Sushmita Khadka, Vineela Kasireddy, Pravash Kumar Dhakal, Chandrakala Dadiboyina |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Journal of Community Hospital Internal Medicine Perspectives |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20009666.2020.1843237 |
Similar Items
-
Efficacy and safety of romiplostim in adult Iraqi patients with refractory immune thrombocytopenia
by: Ali Khazaal Jumaa, et al.
Published: (2020-01-01) -
Oxaliplatin induced acute immune-mediated thrombocytopenia; a case report
by: İsmail Beypinar, et al.
Published: (2017-04-01) -
Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia
by: Min Ji Jeon, et al.
Published: (2020-07-01) -
Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
by: Deirdra R. Terrell, et al.
Published: (2020-11-01) -
Immune neonatal thrombocytopenia - review
by: Ana Isabel Ribeiro Sequeira, et al.
Published: (2020-03-01)